Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Mar 10, 2022
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-03-08+400,000→ 400,000 totalExercise: $0.70Exp: 2032-03-08→ Common Stock (400,000 underlying) - Award
Stock Option (Right to Buy)
2022-03-08+50,000→ 50,000 totalExercise: $0.70Exp: 2032-03-08→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]The stock option will vest in full on March 8, 2023, subject to the Reporting Person's continued service through the vesting date.